Rheumatology

Overview

Journal BMJ

Specialty General Medicine

Date 1998 Jun 24

PMID 9624076

Citations 3

Authors

P Brooks

Affiliations

Soon will be listed here.

Citing Articles

Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients.

Meineke I, Turck D Br J Clin Pharmacol. 2003; 55(1):32-8.

PMID: 12534638 PMC: 1884180. DOI: 10.1046/j.1365-2125.2003.01753.x.

Management of juvenile idiopathic arthritis.

Sawhney S Indian J Pediatr. 2002; 69(10):893-7.

PMID: 12450301 DOI: 10.1007/BF02723715.

Combination treatment is rare in patients with rheumatoid arthritis.

Pal B, Amlesh H BMJ. 1998; 317(7173):1653-4.

PMID: 9848916 PMC: 1114445. DOI: 10.1136/bmj.317.7173.1653a.

References

Seideman P, Samuelson P, NEANDER G . Naproxen and paracetamol compared with naproxen only in coxarthrosis. Increased effect of the combination in 18 patients. Acta Orthop Scand. 1993; 64(3):285-8. DOI: 10.3109/17453679308993626. View

March L, Irwig L, Schwarz J, Simpson J, Chock C, Brooks P . n of 1 trials comparing a non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis. BMJ. 1994; 309(6961):1041-5; discussion 1045-6. PMC: 2541590. DOI: 10.1136/bmj.309.6961.1041. View

McKendry R, Huebsch L, Leclair B . Progression of rheumatoid arthritis following bone marrow transplantation. A case report with a 13-year followup. Arthritis Rheum. 1996; 39(7):1246-53. DOI: 10.1002/art.1780390727. View

Hamilton J, BIGGS J, Atkinson K, Brooks P . Bone marrow transplantation in auto-immune disease. Baillieres Clin Rheumatol. 1995; 9(4):673-87. DOI: 10.1016/s0950-3579(05)80308-5. View

Kirwan J . The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med. 1995; 333(3):142-6. DOI: 10.1056/NEJM199507203330302. View

Fries J . Reevaluating the therapeutic approach to rheumatoid arthritis: the "sawtooth" strategy. J Rheumatol Suppl. 1990; 22:12-5. View

Haagsma C, van Riel P, de Rooij D, Vree T, Russel F, vant Hof M . Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. Br J Rheumatol. 1994; 33(11):1049-55. DOI: 10.1093/rheumatology/33.11.1049. View

Emery P . The Roche Rheumatology Prize Lecture. The optimal management of early rheumatoid disease: the key to preventing disability. Br J Rheumatol. 1994; 33(8):765-8. DOI: 10.1093/rheumatology/33.8.765. View

ODell J, Haire C, Erikson N, Drymalski W, Palmer W, Eckhoff P . Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996; 334(20):1287-91. DOI: 10.1056/NEJM199605163342002. View

10.

Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G . Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med. 1995; 333(3):137-41. DOI: 10.1056/NEJM199507203330301. View

11.

Elliott M, Maini R, Feldmann M, Kalden J, Antoni C, Smolen J . Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994; 344(8930):1105-10. DOI: 10.1016/s0140-6736(94)90628-9. View

12.

Boers M, Verhoeven A, Markusse H, van de Laar M, Westhovens R, van Denderen J . Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997; 350(9074):309-18. DOI: 10.1016/S0140-6736(97)01300-7. View

13.

Distel M, Mueller C, Bluhmki E, Fries J . Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol. 1996; 35 Suppl 1:68-77. DOI: 10.1093/rheumatology/35.suppl_1.68. View

14.

Wynne H, Long A . Patient awareness of the adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs). Br J Clin Pharmacol. 1996; 42(2):253-6. PMC: 2042659. DOI: 10.1046/j.1365-2125.1996.41420.x. View

15.

Ten Wolde S, Breedveld F, Hermans J, Vandenbroucke J, van de Laar M, Markusse H . Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet. 1996; 347(8998):347-52. DOI: 10.1016/s0140-6736(96)90535-8. View

16.

Fries J, Williams C, Morfeld D, Singh G, Sibley J . Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum. 1996; 39(4):616-22. DOI: 10.1002/art.1780390412. View

17.

Campion G, Lebsack M, Lookabaugh J, Gordon G, Catalano M . Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum. 1996; 39(7):1092-101. DOI: 10.1002/art.1780390704. View

18.

Firestein G, Zvaifler N . Anticytokine therapy in rheumatoid arthritis. N Engl J Med. 1997; 337(3):195-7. DOI: 10.1056/NEJM199707173370310. View

19.

McManus P, Primrose J, Henry D, Birkett D, Lindner J, Day R . Pattern of non-steroidal anti-inflammatory drug use in Australia 1990-1994. A report from the Drug Utilization Sub-Committee of the Pharmaceutical Benefits Advisory Committee. Med J Aust. 1996; 164(10):589-92. View

20.

Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner M . Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol. 1996; 3(11):927-33. DOI: 10.1038/nsb1196-927. View